836 related articles for article (PubMed ID: 23637055)
1. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.
Hawton A; Shearer J; Goodwin E; Green C
Appl Health Econ Health Policy; 2013 Aug; 11(4):331-41. PubMed ID: 23637055
[TBL] [Abstract][Full Text] [Related]
2. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
3. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
Allen D; Rixson L
Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.
Caloyeras JP; Zhang B; Wang C; Eriksson M; Fredrikson S; Beckmann K; Knappertz V; Pohl C; Hartung HP; Shah D; Miller JD; Sandbrink R; Lanius V; Gondek K; Russell MW
Clin Ther; 2012 May; 34(5):1132-44. PubMed ID: 22541587
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis.
Kobelt G; Jönsson L; Fredrikson S
Eur J Health Econ; 2003; 4(1):50-9. PubMed ID: 15609169
[TBL] [Abstract][Full Text] [Related]
6. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
7. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
[TBL] [Abstract][Full Text] [Related]
8. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment.
Phillips CJ
CNS Drugs; 2004; 18(9):561-74. PubMed ID: 15222773
[TBL] [Abstract][Full Text] [Related]
9. Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The Netherlands.
Karampampa K; Gustavsson A; van Munster ET; Hupperts RM; Sanders EA; Mostert J; Sinnige OL; de Graaf J; Pop P; Miltenburger C; Groot MT; Relleke M; van der Hel WS
J Med Econ; 2013 Jul; 16(7):939-50. PubMed ID: 23692584
[TBL] [Abstract][Full Text] [Related]
10. Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
Brañas P; Jordan R; Fry-Smith A; Burls A; Hyde C
Health Technol Assess; 2000; 4(27):1-61. PubMed ID: 11074395
[TBL] [Abstract][Full Text] [Related]
11. Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.
Hernandez L; O'Donnell M; Postma M
Pharmacoeconomics; 2018 Oct; 36(10):1223-1252. PubMed ID: 29971666
[TBL] [Abstract][Full Text] [Related]
12. Costs and quality of life of multiple sclerosis in the United Kingdom.
Kobelt G; Berg J; Lindgren P; Kerrigan J; Russell N; Nixon R
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S96-104. PubMed ID: 17310341
[TBL] [Abstract][Full Text] [Related]
13. Direct and indirect costs of Multiple Sclerosis in Baix Llobregat (Catalonia, Spain), according to disability.
Casado V; Martínez-Yélamos S; Martínez-Yélamos A; Carmona O; Alonso L; Romero L; Moral E; Gubieras L; Arbizu T
BMC Health Serv Res; 2006 Nov; 6():143. PubMed ID: 17078879
[TBL] [Abstract][Full Text] [Related]
14. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature.
Naci H; Fleurence R; Birt J; Duhig A
J Med Econ; 2010 Mar; 13(1):78-89. PubMed ID: 20047364
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature.
Dixon S; McKeen E; Tabberer M; Paisley S
Pharmacoeconomics; 2004; 22(7):421-33. PubMed ID: 15137881
[TBL] [Abstract][Full Text] [Related]
16. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers.
Parisé H; Laliberté F; Lefebvre P; Duh MS; Kim E; Agashivala N; Abouzaid S; Weinstock-Guttman B
J Neurol Sci; 2013 Jul; 330(1-2):71-7. PubMed ID: 23647840
[TBL] [Abstract][Full Text] [Related]
17. Multiple sclerosis: relapses, resource use, and costs.
Hawton AJ; Green C
Eur J Health Econ; 2016 Sep; 17(7):875-84. PubMed ID: 26438399
[TBL] [Abstract][Full Text] [Related]
18. Direct and indirect economic consequences of multiple sclerosis in Ireland.
Fogarty E; Walsh C; McGuigan C; Tubridy N; Barry M
Appl Health Econ Health Policy; 2014 Dec; 12(6):635-45. PubMed ID: 25227118
[TBL] [Abstract][Full Text] [Related]
19. Using health state utility values in models exploring the cost-effectiveness of health technologies.
Ara R; Wailoo A
Value Health; 2012; 15(6):971-4. PubMed ID: 22999149
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
